Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2190-9172
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry ; volume:12 ; number:12 ; day:4 ; month:11 ; year:2022 ; pages:2797-2815 ; date:12.2022
Dermatology and therapy ; 12, Heft 12 (4.11.2022), 2797-2815, 12.2022
- Creator
-
Lockshin, Benjamin
Harrison, Ryan W.
McLean, Robert R.
Crabtree, Margaux M.
Konicek, Bruce W.
Zhu, Baojin
Malatestinic, William N.
Atiya, Bilal
Murage, Mwangi J.
Burge, Russel T.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13555-022-00834-7
- URN
-
urn:nbn:de:101:1-2023013121133365216621
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lockshin, Benjamin
- Harrison, Ryan W.
- McLean, Robert R.
- Crabtree, Margaux M.
- Konicek, Bruce W.
- Zhu, Baojin
- Malatestinic, William N.
- Atiya, Bilal
- Murage, Mwangi J.
- Burge, Russel T.
- SpringerLink (Online service)
Other Objects (12)
Secukinumab und Ixekizumab bei Psoriasis: Beträchtlicher Zusatznutzen für bestimmte Patienten
Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
Ixekizumab bei Psoriasis-Arthritis & axialer Spondyloarthritis : umfassende Daten zu Ixekizumab: schnelle und kontinuierliche Wirksamkeit
Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis
Behandlung der Psoriasis mit Secukinumab : Praxisrelevante Hinweise
Ixekizumab (Psoriasis Arthritis) : Addendum zum Auftrag A18-14
Ixekizumab (Psoriasis Arthritis) : Nutzenbewertung gemäß § 35a SGB V
Secukinumab und Ixekizumab bei Psoriasis: Beträchtlicher Zusatznutzen für bestimmte Patienten
Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
Ixekizumab bei Psoriasis-Arthritis & axialer Spondyloarthritis : umfassende Daten zu Ixekizumab: schnelle und kontinuierliche Wirksamkeit
Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis
Behandlung der Psoriasis mit Secukinumab : Praxisrelevante Hinweise
Ixekizumab (Psoriasis Arthritis) : Addendum zum Auftrag A18-14
Ixekizumab (Psoriasis Arthritis) : Nutzenbewertung gemäß § 35a SGB V
Secukinumab und Ixekizumab bei Psoriasis: Beträchtlicher Zusatznutzen für bestimmte Patienten
Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
Ixekizumab bei Psoriasis-Arthritis & axialer Spondyloarthritis : umfassende Daten zu Ixekizumab: schnelle und kontinuierliche Wirksamkeit
Secukinumab (Cosentyx®) flexibel dosieren bei Plaque-Psoriasis
Behandlung der Psoriasis mit Secukinumab : Praxisrelevante Hinweise
Ixekizumab (Psoriasis Arthritis) : Addendum zum Auftrag A18-14